We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

295 hedge funds and large institutions have $2.05B invested in Ultragenyx Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 125 increasing their positions, 83 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

51% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 83

29% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 48

4.16% more ownership

Funds ownership: 97.37% → 101.53% (+4.2%)

3% more funds holding

Funds holding: 287 → 295 (+8)

8% more call options, than puts

Call options by funds: $27.9M | Put options by funds: $25.8M

5% less capital invested

Capital invested by funds: $2.16B → $2.05B (-$108M)

Holders
295
Holders Change
+8
Holders Change %
+2.79%
% of All Funds
3.63%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
62
Increased
125
Reduced
83
Closed
48
Calls
$27.9M
Puts
$25.8M
Net Calls
+$2.02M
Net Calls Change
-$26.3M

Top Buyers

1
AQR Capital Management
AQR Capital Management
Connecticut
+$72.5M
2
SI
Sofinnova Investments
California
+$69M
3
BG
Bellevue Group
Switzerland
+$53.5M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$46.3M
5
Two Sigma Investments
Two Sigma Investments
New York
+$40.1M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$84M
2
BBA
Baker Bros. Advisors
New York
-$63.8M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$53.6M
4
SCM
Suvretta Capital Management
New York
-$46.4M
5
BNP Paribas Asset Management
BNP Paribas Asset Management
France
-$33.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
101
California State Teachers Retirement System (CalSTRS)
California
$2.19M +$480K +21,313 +26%
RhumbLine Advisers
102
RhumbLine Advisers
Massachusetts
$2.17M +$35.6K +1,581 +2%
PA
103
Pinnacle Associates
New York
$2.15M -$199K -8,850 -8%
CAG
104
Crestwood Advisors Group
Massachusetts
$2.1M -$1.01K -45 -0%
FISPB
105
Fideuram - Intesa Sanpaolo Private Banking
$2.09M +$871K +38,666 +63%
AC
106
AXQ Capital
New Jersey
$2.01M +$2.17M +96,177 New
State Board of Administration of Florida Retirement System
107
State Board of Administration of Florida Retirement System
Florida
$1.97M -$67.7K -3,008 -3%
AI
108
Atom Investors
Texas
$1.96M +$2.11M +93,622 New
SEI Investments
109
SEI Investments
Pennsylvania
$1.93M -$1.39M -61,632 -40%
EGM
110
Engineers Gate Manager
New York
$1.87M +$287K +12,753 +17%
OAM
111
OP Asset Management
$1.82M +$1.96M +86,917 New
HCA
112
Harbor Capital Advisors
Illinois
$1.74M +$1.87M +83,196 New
N
113
Natixis
France
$1.71M +$1.84M +81,754 New
MFAM
114
Motley Fool Asset Management
Virginia
$1.64M +$128K +5,693 +8%
VAM
115
Vanguard Asset Management
$1.63M +$1.75M +77,666 New
NICM
116
Neo Ivy Capital Management
New York
$1.54M +$1.66M +73,601 New
PA
117
Profund Advisors
Maryland
$1.51M +$349K +15,484 +27%
Deutsche Bank
118
Deutsche Bank
Germany
$1.51M -$11.9M -527,604 -88%
Mirae Asset Global ETFs Holdings
119
Mirae Asset Global ETFs Holdings
Hong Kong
$1.48M +$120K +5,336 +8%
GC
120
Guggenheim Capital
Illinois
$1.44M +$443K +19,666 +40%
Wells Fargo
121
Wells Fargo
California
$1.44M +$117K +5,202 +8%
ACM
122
Aquatic Capital Management
Illinois
$1.43M -$433K -19,242 -22%
OL
123
Odyssean LLC
Connecticut
$1.41M +$1.02M +45,182 +203%
EP
124
Eversept Partners
New York
$1.31M -$5.73M -254,607 -80%
BC
125
Birchview Capital
Vermont
$1.3M – – –
3 4
5
6 7

RARE Hedge Fund Activity: Q1 2026 in Review

295 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2026, worth a combined $2.05B — down 5% from $2.16B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new RARE positions and 48 closed out — a net gain of 14 holders — while 125 added to existing stakes and 83 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $72.5M. The largest seller was JP Morgan Chase, cutting an estimated $84M.

  • 295 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2026, up from 287 in Q4 2025.
  • Funds reported $2.05B of Ultragenyx Pharmaceutical stock for Q1 2026, down 5% quarter-over-quarter.
  • 62 funds opened new Ultragenyx Pharmaceutical positions in Q1 2026 and 48 closed out, a net change of +14 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q1 2026 was AQR Capital Management, an estimated $72.5M added.
  • The largest Ultragenyx Pharmaceutical seller in Q1 2026 was JP Morgan Chase, an estimated $84M sold.

Based on aggregated 13F filings for Q1 2026.